User:Mr. Ibrahem/Lenvatinib

Mr. Ibrahem/Lenvatinib
Clinical data
Trade names	Lenvima, Kisplyx, others
Other names	E7080
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US DailyMed: Lenvatinib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
Drug class	Tyrosine kinase inhibitor
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	85% (estimated)
Protein binding	98–99%
Metabolism	CYP3A4, aldehyde oxidase, non-enzymatic
Metabolites	Desmethyl-lenvatinib (M2) and others
Elimination half-life	28 hours
Excretion	~65% feces, 25% urine
Identifiers
	IUPAC name 4-[3-Chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide;
Chemical and physical data
Formula	C21H19ClN4O4
Molar mass	426.86 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C4CC4NC(=O)Nc3ccc(cc3Cl)Oc1ccnc(cc2OC)c1cc2C(=O)N;
	InChI InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28) ; Key:WOSKHXYHFSIKNG-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lenvatinib, sold under the brand name Lenvima among others, is medication used to treat certain types of thyroid cancer, renal cell cancer, and hepatocellular carcinoma.^[2]^[3] For thyroid cancer, it is used when radioactive iodine is not effective.^[1] It is taken by mouth.^[1]

Common side effects include high blood pressure, diarrhea, weight loss, nausea, inflammation of the mouth, headache, and rash.^[2] Other side effects may include kidney problems, heart failure, blood clots, bleeding in the brain, and liver problems.^[2] Use in pregnancy may harm the baby.^[1] It is a tyrosine kinase inhibitor against VEGFR1, VEGFR2 and VEGFR3.^[1]

Lenvatinib was approved for medical use in the United States and Europe in 2015.^[1]^[2] In the United Kingdom it costs the NHS about £1,400 at a dose of 10 mg per day for a month as of 2021.^[3] In the United States this amount is about 21,300 USD.^[4]

References

^ ^a ^b ^c ^d ^e ^f "Lenvatinib Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 21 November 2021.
^ ^a ^b ^c ^d ^e ^f "Lenvima". Archived from the original on 24 June 2021. Retrieved 21 November 2021.
^ ^a ^b ^c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1033. ISBN 978-0857114105.
^ "Lenvima Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 January 2021. Retrieved 21 November 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f "Lenvatinib Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 21 November 2021.

[EPAR2021-2] ^ ^a ^b ^c ^d ^e ^f "Lenvima". Archived from the original on 24 June 2021. Retrieved 21 November 2021.

[BNF81-3] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1033. ISBN 978-0857114105.

[4] "Lenvima Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 January 2021. Retrieved 21 November 2021.

[1]

[2]

[3]

[4]